KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Current Deferred Revenue (2020 - 2021)

Historic Current Deferred Revenue for Castle Biosciences (CSTL) over the last 2 years, with Q3 2021 value amounting to $3.0 million.

  • Castle Biosciences' Current Deferred Revenue fell 6408.38% to $3.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $3.0 million, marking a year-over-year decrease of 6408.38%. This contributed to the annual value of $6.6 million for FY2020, which is N/A changed from last year.
  • Per Castle Biosciences' latest filing, its Current Deferred Revenue stood at $3.0 million for Q3 2021, which was down 6408.38% from $6.2 million recorded in Q2 2021.
  • Castle Biosciences' 5-year Current Deferred Revenue high stood at $8.4 million for Q2 2020, and its period low was $3.0 million during Q3 2021.